BioNTech SE (NASDAQ: BNTX) reported Q3 EPS of EUR12.35, versus (EUR0.88) reported last year. Revenue for the quarter came in at EUR6.09 billion, versus EUR67.5 million reported last year.

Guidance:

Estimated BioNTech COMIRNATY/COVID-19 vaccine revenues for the full 2021 financial year based on up to 2.5 billion doses: ~€16 billion to €17 billion2

For earnings history and earnings-related data on BioNTech SE (BNTX) click here.